Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Income (Loss) per Common Share (Tables)

9 Months Ended

Aug. 31, 2019

The following table sets forth the calculation of basic and diluted net income (loss) per common share:


	Three Months Ended				Nine Months Ended
	August 31, 2019		August 31, 2018		August 31, 2019		August 31, 2018
Numerator:
Net Income (Loss)	$	1,116,259	$	244,984	$	1,445,809	($	1,745,582	)

Denominator:
Weighted-average shares outstanding-basic		7,803,333		7,694,662		7,802,676		7,350,868
Dilutive common shares issuable upon exercise of stock options		641,904		681,013		627,575		—

Weighted-average shares-diluted		8,445,237		8,375,675		8,430,251		7,350,868

Net income (loss) per common share:
Basic	$	0.14	$	0.03	$	0.19	($	0.24	)

Diluted	$	0.13	$	0.03	$	0.17	($	0.24	)